Mammary Cell News Volume 7.44 | Nov 12 2015

Amphiregulin Is a Critical Downstream Effector of Estrogen Signaling in ERα-Positive Breast Cancer
Researchers investigated the role of amphiregulin in breast cancer cell proliferation using human tissue samples and tumor xenografts in mice. [Cancer Res] Abstract

The Ascidian Natural Product Eusynstyelamide B Is a Novel Topoisomerase II Poison that Induces DNA Damage and Growth Arrest in Prostate and Breast Cancer Cells
The authors investigated the mechanism of action of eusynstyelamide B in cancer cell lines of the prostate and breast. [Oncotarget] Full Article

Activation of the Farnesoid X-Receptor in Breast Cancer Cell Lines Results in Cytotoxicity but Not Increased Migration Potential
Investigators showed that activation of the nuclear receptor arnesoid x-receptor, either by its endogenous ligand chenodexoycholic acid or the synthetic GW4064, leads to cell death in four breast cancer cell lines with distinct phenotypes: MCF-10A (normal), MCF-7 (receptor positive), MDA-MB-231 and MDA-MB-468 (triple negative). [Cancer Lett] Abstract

An EGFR/Src-Dependent β4 Integrin/FAK Complex Contributes to Malignancy of Breast Cancer
The authors demonstrated physical and functional interactions between β4 integrin and focal adhesion kinase (FAK) that influence breast cancer malignancy. [Sci Rep] Full Article

Exosomes Decrease Sensitivity of Breast Cancer Cells to Adriamycin by Delivering MicroRNAs
Scientists explored the relevance of exosome-mediated microRNA (miRNA) delivery in resistance transmission of adriamycin (adr)-resistant breast cancer (BCa) sublines. They demonstrated the selective packing of miRNAs within the exosomes derived from adr-resistant BCa cells. [Tumour Biol] Abstract

Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer
Investigators showed that PIK3CA mutations and PI3K/AKT pathway activation are common events in triple negative breast cancer. [PLoS One] Full Article

A Nanobody Activation Immunotherapeutic that Selectively Destroys HER2-Positive Breast Cancer Cells
Researchers report a rationally designed nanobody activation immunotherapeutic that selectively redirects anti-dinitrophenyl antibodies to the surface of HER2-positive breast cancer cells, resulting in their targeted destruction by antibody-dependent cellular cytotoxicity. [Chembiochem] Abstract

CLINICAL RESEARCH

ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer
Researchers investigated the clinical value of estrogen-related receptor alpha (ERRα) in randomized cohorts of tamoxifen-treated and adjuvant-untreated patients. [Clin Cancer Res] Abstract

A Phase II Randomized Study of Lapatinib in Combination with Capecitabine, Vinorelbine or Gemcitabine in Patients with HER2 Positive Metastatic Breast Cancer Who Progressed after a Taxane (LACOG 0801)
In this Phase II, multicenter study, patients with HER2 positive metastatic breast cancer progressing after taxane were randomized between lapatinib 1250 mg in combination with: C 2000 mg/m² days 1 to 14, vinorelbine 25 mg/m² days 1 and 8 or gemcitabine 1000 mg/m² days 1 and 8, every 21 days. [Clin Breast Cancer] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

GSK and Merck to Study Immunotherapy Combination as Potential Cancer Treatment
GSK and Merck announced the initiation of a Phase I clinical trial designed to evaluate GSK’s investigational immunotherapy GSK3174998 as monotherapy and in combination with Merck’s anti-PD-1 therapy, Keytruda^® in patients with locally advanced, recurrent or metastatic solid tumor(s) that have progressed after standard treatment. [GlaxoSmithKline plc] Press Release

From our sponsor:
Webinar: Neural Stem Cell Culture Systems – Neurosphere vs. Adherent Monolayer Culture. Watch now.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the mammary cell community.

NEW Postdoctoral Research Fellow – Ovarian and Breast Cancer (Fred Hutchinson Cancer Research Center)

Academic Breast Pathologist (Beth Israel Deaconess Medical Center)

Group Leader Position – Cancer Research (Oslo University Hospital)

Higher Scientific Officer – Breast Cancer Research (Institute of Cancer Research)

Postdoctoral Fellow – Metastatic Breast Cancer (Purdue University Center for Cancer Research)

Biological Imaging Scientist – 3D Cellular Models of Organs and Disease (University of Pittsburgh Drug Discovery Institute)

Postdoctoral Fellow – Tumor Dormancy (Fred Hutchinson Cancer Research Center)

Postdoctoral Research Fellow – Metastatic Breast Cancer (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.